Rhenman & Partners Asset Management Ab Biogen Inc. Transaction History

Rhenman & Partners Asset Management Ab

$1.01 Billion
Q2 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Biogen Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 84,800 shares of BIIB stock, worth $14.8 Million. This represents 1.94% of its overall portfolio holdings.

Number of Shares

84,800

Previous 56,800 49.3%

Holding current value

$14.8 Million

Previous $12.2 Million 60.51%

% of portfolio

1.94%

Previous 1.2%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$190.52 - $236.72 $5.33 Million - $6.63 Million	28,000 Added 49.3%	84,800 $19.7 Million
Q1 2024 May 14, 2024	SELL	$212.02 - $267.71 $396,901 - $501,153	-1,872 Reduced 3.19%	56,800 $12.2 Million
Q4 2023 Feb 13, 2024	BUY	$222.59 - $267.94 $483,465 - $581,965	2,172 Added 3.84%	58,672 $15.2 Million
Q3 2023 Nov 13, 2023	SELL	$253.3 - $285.89 $2.03 Million - $2.29 Million	-8,000 Reduced 12.4%	56,500 $14.5 Million
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $4.68 Million - $5.41 Million	17,000 Added 35.79%	64,500 $18.4 Million
Q1 2023 May 11, 2023	BUY	$256.56 - $292.34 $4.49 Million - $5.12 Million	17,500 Added 58.33%	47,500 $13.2 Million
Q4 2022 Feb 13, 2023	SELL	$252.44 - $306.72 $702,288 - $853,295	-2,782 Reduced 8.49%	30,000 $8.31 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $6.38 Million - $8.8 Million	32,782 New	32,782 $9.29 Million
Q2 2022 Aug 12, 2022	SELL	$187.54 - $223.02 $2.81 Million - $3.35 Million	-15,000 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$193.77 - $244.14 $19.4 Million - $24.4 Million	-100,000 Reduced 86.96%	15,000 $3.16 Million
Q4 2021 Feb 11, 2022	SELL	$223.92 - $287.77 $7.84 Million - $10.1 Million	-35,000 Reduced 23.33%	115,000 $27.6 Million
Q3 2021 Nov 12, 2021	BUY	$282.99 - $369.05 $17 Million - $22.1 Million	60,000 Added 66.67%	150,000 $42.4 Million
Q2 2021 Aug 13, 2021	BUY	$259.0 - $414.71 $18.3 Million - $29.2 Million	70,500 Added 361.54%	90,000 $31.2 Million
Q1 2021 May 14, 2021	SELL	$242.95 - $284.63 $4.98 Million - $5.83 Million	-20,500 Reduced 51.25%	19,500 $5.46 Million
Q4 2020 Jan 19, 2021	BUY	$236.26 - $355.63 $1.65 Million - $2.49 Million	7,000 Added 21.21%	40,000 $9.79 Million
Q3 2020 Oct 13, 2020	BUY	$264.77 - $305.71 $4.24 Million - $4.89 Million	16,000 Added 94.12%	33,000 $9.36 Million
Q2 2020 Jul 16, 2020	SELL	$258.66 - $342.55 $2.07 Million - $2.74 Million	-8,000 Reduced 32.0%	17,000 $4.55 Million
Q1 2020 Apr 16, 2020	BUY	$268.85 - $341.04 $1.34 Million - $1.71 Million	5,000 Added 25.0%	25,000 $7.91 Million
Q4 2019 Jan 17, 2020	BUY	$220.06 - $304.07 $4.4 Million - $6.08 Million	20,000 New	20,000 $5.94 Million
Q1 2019 Apr 11, 2019	SELL	$216.71 - $338.96 $13 Million - $20.3 Million	-60,000 Closed	0 $0
Q4 2018 Feb 05, 2019	BUY	$278.5 - $352.75 $8.36 Million - $10.6 Million	30,000 Added 100.0%	60,000 $18.1 Million
Q3 2018 Oct 03, 2018	BUY	$293.51 - $383.83 $4.99 Million - $6.53 Million	17,000 Added 130.77%	30,000 $10.6 Million
Q2 2018 Jul 20, 2018	SELL	$257.52 - $306.91 $7.55 Million - $8.99 Million	-29,300 Reduced 69.27%	13,000 $3.77 Million
Q1 2018 Apr 11, 2018	BUY	$260.13 - $367.91 $7.02 Million - $9.93 Million	27,000 Added 176.47%	42,300 $11.6 Million
Q4 2017 Jan 19, 2018	SELL	$307.64 - $344.58 $2.06 Million - $2.31 Million	-6,700 Reduced 30.45%	15,300 $4.87 Million
Q3 2017 Oct 13, 2017	BUY	$281.15 - $329.69 $6.19 Million - $7.25 Million	22,000	22,000 $6.89 Million

Others Institutions Holding BIIB

# of Institutions

1,022

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Biogen Inc. Transaction History